Sihuan Pharmaceutical Holdings Stock Cash And Equivalents
Sihuan Pharmaceutical Holdings fundamentals help investors to digest information that contributes to Sihuan Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Sihuan Pink Sheet. The fundamental analysis module provides a way to measure Sihuan Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sihuan Pharmaceutical pink sheet.
Sihuan |
Sihuan Pharmaceutical Holdings Company Cash And Equivalents Analysis
Sihuan Pharmaceutical's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Sihuan Pharmaceutical Cash And Equivalents | 5.25 B |
Most of Sihuan Pharmaceutical's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sihuan Pharmaceutical Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Sihuan Pharmaceutical Holdings has 5.25 B in Cash And Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all United States stocks is 94.29% lower than that of the firm.
Sihuan Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sihuan Pharmaceutical's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sihuan Pharmaceutical could also be used in its relative valuation, which is a method of valuing Sihuan Pharmaceutical by comparing valuation metrics of similar companies.Sihuan Pharmaceutical is currently under evaluation in cash and equivalents category among its peers.
Sihuan Fundamentals
| Return On Equity | -0.0487 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 506.36 M | |||
| Shares Outstanding | 9.33 B | |||
| Shares Owned By Insiders | 55.02 % | |||
| Shares Owned By Institutions | 4.21 % | |||
| Price To Earning | 8.75 X | |||
| Price To Book | 0.81 X | |||
| Price To Sales | 0.41 X | |||
| Revenue | 3.29 B | |||
| Gross Profit | 2.45 B | |||
| EBITDA | 914.73 M | |||
| Net Income | 416.51 M | |||
| Cash And Equivalents | 5.25 B | |||
| Cash Per Share | 0.56 X | |||
| Total Debt | 844.75 M | |||
| Debt To Equity | 0.14 % | |||
| Current Ratio | 2.43 X | |||
| Book Value Per Share | 0.78 X | |||
| Cash Flow From Operations | 665.29 M | |||
| Earnings Per Share | 0.01 X | |||
| Number Of Employees | 3.9 K | |||
| Beta | 0.8 | |||
| Market Capitalization | 1.2 B | |||
| Total Asset | 14.5 B | |||
| Retained Earnings | 5.54 B | |||
| Working Capital | 4.66 B | |||
| Current Asset | 6.17 B | |||
| Current Liabilities | 1.51 B | |||
| Z Score | 0.6 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 14.5 B | |||
| Last Dividend Paid | 0.014 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Sihuan Pink Sheet
If you are still planning to invest in Sihuan Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sihuan Pharmaceutical's history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |